California does not have the legal basis to list areca nut (the seed of Areca catechu) and betel quid as chemicals known to cause cancer, according to comments filed by the American Herbal Products Association Nov. 21. According to AHPA President Michael McGuffin, the state's Office of Environmental Health Hazard Assessment (OEHHA) is using a "labor code shortcut instead of calling a public meeting" where public comment could, and should, be obtained. In addition, AHPA requests that any listing by the state apply only to areca seed (not husk) intended for prolonged chewing. Swallowing the seed in a dietary supplement has no known health consequences, according to AHPA. The International Agency for Research on Cancer recently released findings linking negative health consequences with chewing areca nut and betel quid...
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
Generative artificial intelligence tools, such as ChatGPT, have “democratized” AI, and contract research organizations are wholeheartedly embracing these tools, given their focus on efficiency, says Stephen Pyke, who chairs the AI committee at the Association of Clinical Research Organizations.
Japan gives world-first approval recommendations to two domestically originated drugs, for insomnia and glaucoma/ocular hypertension.
The FDA could act on 17 applications, including 10 novel agents, during August. Only one would be a second-cycle review.
